Stay updated on Safety of Selonsertib, Firsocostat, & Cilofexor in NASH Clinical Trial
Sign up to get notified when there's something new on the Safety of Selonsertib, Firsocostat, & Cilofexor in NASH Clinical Trial page.

Latest updates to the Safety of Selonsertib, Firsocostat, & Cilofexor in NASH Clinical Trial page
- Check6 days agoChange DetectedThe page revision tag was updated from v3.6.3 to v3.6.4, indicating an behind-the-scenes update to the page's template or build without altering the visible study content.SummaryDifference0.0%

- Check13 days agoChange DetectedSteatotic Liver Disease has been added as a term, and Fatty Liver Disease has been removed, updating the terminology used to describe the liver condition in this study page. This reflects a shift in nomenclature for NAFLD/NASH-related conditions and affects how the study's conditions are described and discovered on the page.SummaryDifference0.0%

- Check20 days agoNo Change Detected
- Check28 days agoChange DetectedThe page now displays revision v3.6.3, replacing the previous v3.6.2. This represents a minor update to the page's versioning/metadata and does not affect the displayed study details.SummaryDifference0.0%

- Check35 days agoChange DetectedRevision updated from v3.6.0 to v3.6.2, reflecting a small page build update.SummaryDifference0.0%

- Check49 days agoChange DetectedThe study page now states that it is no longer recruiting participants and adds new sections to help users read the study record, answer common questions, and understand how to join a study, with the revision updated to v3.6.0.SummaryDifference0.3%

- Check56 days agoChange DetectedThe revision tag on the page was updated from v3.5.4 to v3.5.5, indicating a newer version of the page's documentation.SummaryDifference0.0%

Stay in the know with updates to Safety of Selonsertib, Firsocostat, & Cilofexor in NASH Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of Selonsertib, Firsocostat, & Cilofexor in NASH Clinical Trial page.